Checkpoint inhibitors in relapsed refractory Hodgkin Lymphoma
Expert: Astrid Pavlovsky, Clinical Research Center - FUNDALEU, Buenos Aires, Argentina
1 - Why do chemorefractory patients respond to checkpoint inhibitors?
2 - Can you comment on the design and results of the KEYNOTE 204 for patients with RR HL?
3 - What do you think are the future challenges and therapeutic options in this group of patients?
Create your
podcast in
minutes
It is Free